Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma

Neurological adverse events of immune checkpoint inhibitor (ICI) therapy mostly develop within 3 months after initiation of ICI treatment. An 82-year-old male with malignant pleural mesothelioma developed anti-Ma2-associated limbic encephalitis at a delay of 18 months after the start of nivolumab th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Rei, Tanabe, Etsuko, Otsuka, Yoshihisa, Yoneda, Yukihiro, Kageyama, Yasufumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Single Case − General Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647130/
https://www.ncbi.nlm.nih.gov/pubmed/34950011
http://dx.doi.org/10.1159/000519763
_version_ 1784610554666549248
author Hashimoto, Rei
Tanabe, Etsuko
Otsuka, Yoshihisa
Yoneda, Yukihiro
Kageyama, Yasufumi
author_facet Hashimoto, Rei
Tanabe, Etsuko
Otsuka, Yoshihisa
Yoneda, Yukihiro
Kageyama, Yasufumi
author_sort Hashimoto, Rei
collection PubMed
description Neurological adverse events of immune checkpoint inhibitor (ICI) therapy mostly develop within 3 months after initiation of ICI treatment. An 82-year-old male with malignant pleural mesothelioma developed anti-Ma2-associated limbic encephalitis at a delay of 18 months after the start of nivolumab therapy (3 months after termination of a 15-month course of ICI treatment). Immunotherapy with steroids and immunoglobulins resulted in moderate neurological improvement. Over the next year, malignant pleural mesothelioma gradually worsened, while the anti-Ma2 antibody test remained positive. Anti-Ma2 paraneoplastic encephalitis may occur after a delay following the discontinuation of ICI therapy.
format Online
Article
Text
id pubmed-8647130
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-86471302021-12-22 Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma Hashimoto, Rei Tanabe, Etsuko Otsuka, Yoshihisa Yoneda, Yukihiro Kageyama, Yasufumi Case Rep Neurol Single Case − General Neurology Neurological adverse events of immune checkpoint inhibitor (ICI) therapy mostly develop within 3 months after initiation of ICI treatment. An 82-year-old male with malignant pleural mesothelioma developed anti-Ma2-associated limbic encephalitis at a delay of 18 months after the start of nivolumab therapy (3 months after termination of a 15-month course of ICI treatment). Immunotherapy with steroids and immunoglobulins resulted in moderate neurological improvement. Over the next year, malignant pleural mesothelioma gradually worsened, while the anti-Ma2 antibody test remained positive. Anti-Ma2 paraneoplastic encephalitis may occur after a delay following the discontinuation of ICI therapy. S. Karger AG 2021-11-08 /pmc/articles/PMC8647130/ /pubmed/34950011 http://dx.doi.org/10.1159/000519763 Text en Copyright © 2021 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Single Case − General Neurology
Hashimoto, Rei
Tanabe, Etsuko
Otsuka, Yoshihisa
Yoneda, Yukihiro
Kageyama, Yasufumi
Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
title Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
title_full Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
title_fullStr Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
title_full_unstemmed Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
title_short Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
title_sort anti-ma2-associated limbic encephalitis after termination of immune checkpoint inhibitor therapy for malignant pleural mesothelioma
topic Single Case − General Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647130/
https://www.ncbi.nlm.nih.gov/pubmed/34950011
http://dx.doi.org/10.1159/000519763
work_keys_str_mv AT hashimotorei antima2associatedlimbicencephalitisafterterminationofimmunecheckpointinhibitortherapyformalignantpleuralmesothelioma
AT tanabeetsuko antima2associatedlimbicencephalitisafterterminationofimmunecheckpointinhibitortherapyformalignantpleuralmesothelioma
AT otsukayoshihisa antima2associatedlimbicencephalitisafterterminationofimmunecheckpointinhibitortherapyformalignantpleuralmesothelioma
AT yonedayukihiro antima2associatedlimbicencephalitisafterterminationofimmunecheckpointinhibitortherapyformalignantpleuralmesothelioma
AT kageyamayasufumi antima2associatedlimbicencephalitisafterterminationofimmunecheckpointinhibitortherapyformalignantpleuralmesothelioma

Ejemplares similares